You are here

Alkoxylamine nucleosides for sequencing by synthesis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42HG003668-02A1
Agency Tracking Number: HG003668
Amount: $933,083.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
INTELLIGENT BIO-SYSTEMS, INC. 34 Bear Hill Rd.
Waltham, MA 02451
United States
DUNS: 170777770
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STEVEN BENNER
 (352) 271-7005
 SBENNER@FFAME.ORG
Business Contact
Phone: (781) 466-8050
Email: sgordon@alum.mit.edu
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Sequencing during synthesis (SdS) is an architecture for massively parallel DNA sequencing that has the strong potential of lowering the cost of sequencing enough to allow individuals access to their own genetic heritag
e as a way of personalizing their medical care. Thus far, however, higher-throughput next-generation sequencing systems are relatively expensive, have relatively long run times and produce relatively short reads, thereby limiting their use for diagnostic a
pplications. This proposal will support the transfer of reagent technology from the Foundation for Applied Molecular Evolution (FfAME) to Intelligent Bio-Systems (IBS), where it will be optimized to yield, at the end of the Phase 2 period, a high-performan
ce prototype instrument that better meets the needs of both the research and healthcare communities. PUBLIC HEALTH RELEVANCE: Sequencing during synthesis (SdS) is an architecture for doing massively parallel DNA sequencing that has the strong potent
ial of lowering the cost of sequencing enough to allow individuals access to their own genetic heritage as a way of personalizing their medical care. Intelligent Bio-Systems (IBS) seeks to become the cost and quality leader in this next generation of DNA s
equencing technology. This proposal will support the transfer of reagent technology from the Foundation for Applied Molecular Evolution (FfAME) to IBS, where it will be optimized for the IBS instrument to yield, at the end of the Phase 2 period, a commerci
al instrument.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government